NOVOLOG
NOVOLOG is a rapid-acting human insulin analog indicated to improve glycemic control. It is approved for use in both adult and pediatric patients with diabetes mellitus. This medication serves as a therapeutic option for managing blood sugar levels in patients with these metabolic conditions.
How NOVOLOG Works
The primary activity of NOVOLOG is the regulation of glucose metabolism. It lowers blood glucose by stimulating peripheral glucose uptake in skeletal muscle and fat while inhibiting hepatic glucose production. Furthermore, it inhibits lipolysis and proteolysis and enhances protein synthesis.
Details
- Status
- Prescription
- First Approved
- 2000-06-07
- Routes
- SUBCUTANEOUS
- Dosage Forms
- INJECTABLE
NOVOLOG Approval History
What NOVOLOG Treats
1 indicationsNOVOLOG is approved for 1 conditions since its original approval in 2000. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Diabetes
Drugs Similar to NOVOLOG
FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
NOVOLOG FDA Label Details
ProIndications & Usage
FDA Label (PDF)NOVOLOG is indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus. NOVOLOG is rapid acting human insulin analog indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus .
Want competitive intelligence?
See who's developing similar drugs and track their progress
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.